[{"id":"58481425-6a53-4802-b306-7ed470c87380","acronym":"","url":"https://clinicaltrials.gov/study/NCT04221542","created_at":"2021-01-18T20:32:52.184Z","updated_at":"2025-02-25T16:52:48.663Z","phase":"Phase 1","brief_title":"Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT04221542","lead_sponsor":"Amgen","biomarkers":" STEAP1","pipe":"","alterations":" ","tags":["STEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Xtandi (enzalutamide) • abiraterone acetate • xaluritamig (AMG 509)"],"overall_status":"Recruiting","enrollment":" Enrollment 470","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 04/15/2026","primary_completion_date":" 04/15/2026","study_txt":" Completion: 08/17/2028","study_completion_date":" 08/17/2028","last_update_posted":"2025-02-04"},{"id":"00e8ec23-03be-49d1-9f43-a54b7be00360","acronym":"","url":"https://clinicaltrials.gov/study/NCT06555796","created_at":"2025-02-25T17:03:57.511Z","updated_at":"2025-02-25T17:03:57.511Z","phase":"Phase 1","brief_title":"Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer","source_id_and_acronym":"NCT06555796","lead_sponsor":"Amgen","biomarkers":" STEAP1","pipe":"","alterations":" ","tags":["STEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e xaluritamig (AMG 509)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/23/2024","start_date":" 09/23/2024","primary_txt":" Primary completion: 09/22/2026","primary_completion_date":" 09/22/2026","study_txt":" Completion: 03/23/2029","study_completion_date":" 03/23/2029","last_update_posted":"2025-02-03"},{"id":"68cc78ab-dc4e-4e90-9e23-e14c4cde86a7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06613100","created_at":"2025-02-26T09:23:12.905Z","updated_at":"2025-02-26T09:23:12.905Z","phase":"Phase 1","brief_title":"Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer","source_id_and_acronym":"NCT06613100","lead_sponsor":"Amgen","biomarkers":" STEAP1","pipe":"","alterations":" ","tags":["STEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e xaluritamig (AMG 509)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/25/2024","start_date":" 11/25/2024","primary_txt":" Primary completion: 06/21/2026","primary_completion_date":" 06/21/2026","study_txt":" Completion: 10/25/2029","study_completion_date":" 10/25/2029","last_update_posted":"2024-12-16"}]